Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
SHANGHAI, July 26, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the completion of dosing for all HNVs in the Phase I clinical study of its novel Ketorolac for IV infusion (NTM-001), a non-opioid analgesic drug co-developed with N
Nuance Pharma advances Rare Disease R&D with CORD
July 11th, 2022, Mr. Mark Lotter, founder and CEO of Nuance Pharma, visited Chinese Organization for Rare Disorders (CORD) and met with Mr. Huang Rufang, founder and president of CORD.
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs
Strategic Cooperation Agreement with SHAPHAR
June 16th, 2022, Nuance Pharma signed Strategic Cooperation Agreement with Shanghai Pharmaceutical Co., Ltd. (Shanghai Pharma).
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Top-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1 around the end of 2022
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
HAMILTON, BERMUDA / ACCESSWIRE / March 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
SHANGHAI, Jan. 6, 2022 /PRNewswire/ -- Nuance Pharma ("Nuance"or the "Company"), a specialty care focused biopharma with late late-stage clinical programs and existing commercial operations, today announced an agreement with Sino Healt